Log in

NASDAQ:MBIOMustang Bio Stock Price, Forecast & News

$3.13
-0.06 (-1.88 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.05
Now: $3.13
$3.19
50-Day Range
$3.06
MA: $3.44
$4.60
52-Week Range
$1.78
Now: $3.13
$4.85
Volume601,600 shs
Average Volume1.13 million shs
Market Capitalization$134.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase I/II clinical trials. The company also develops CD123, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; CD20 for immunotherapy of B-cell lymphomas; CS1, an NK cell receptor regulating immune functions; IL13Ra2 CAR T cell program for glioblastoma; HER2 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; and PSCA CAR T for prostate and pancreatic cancers. It has a license agreement with Harvard University for the treatment of cancer; Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More
Mustang Bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.78 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBIO
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.25 per share

Profitability

Net Income$-46,390,000.00

Miscellaneous

Employees38
Market Cap$134.09 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive MBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.

Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

How has Mustang Bio's stock been impacted by COVID-19 (Coronavirus)?

Mustang Bio's stock was trading at $2.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MBIO stock has increased by 33.2% and is now trading at $3.13. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mustang Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mustang Bio.

When is Mustang Bio's next earnings date?

Mustang Bio is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Mustang Bio.

How were Mustang Bio's earnings last quarter?

Mustang Bio Inc (NASDAQ:MBIO) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.28) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.03. View Mustang Bio's earnings history.

What price target have analysts set for MBIO?

3 brokers have issued 12 month target prices for Mustang Bio's shares. Their forecasts range from $7.00 to $13.00. On average, they anticipate Mustang Bio's stock price to reach $9.00 in the next year. This suggests a possible upside of 187.5% from the stock's current price. View analysts' price targets for Mustang Bio.

Has Mustang Bio been receiving favorable news coverage?

Media stories about MBIO stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mustang Bio earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Mustang Bio.

Are investors shorting Mustang Bio?

Mustang Bio saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,050,000 shares, an increase of 297.0% from the June 15th total of 264,500 shares. Based on an average trading volume of 619,700 shares, the short-interest ratio is presently 1.7 days. Approximately 3.7% of the company's shares are sold short. View Mustang Bio's Current Options Chain.

Who are some of Mustang Bio's key competitors?

What other stocks do shareholders of Mustang Bio own?

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the following people:
  • Mr. Michael S. Weiss, Exec. Chairman (Age 53)
  • Dr. Manuel Litchman, Pres, CEO & Director (Age 65)
  • Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 51)
  • Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 54)
  • Dr. Knut Niss, Chief Technology Officer

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by many different institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.58%). Company insiders that own Mustang Bio stock include Lindsay A Md Rosenwald and Manuel Md Litchman. View institutional ownership trends for Mustang Bio.

Which institutional investors are buying Mustang Bio stock?

MBIO stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Mustang Bio stock in the last two years include Lindsay A Md Rosenwald, and Manuel Md Litchman. View insider buying and selling activity for Mustang Bio.

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $3.13.

How big of a company is Mustang Bio?

Mustang Bio has a market capitalization of $134.09 million. The company earns $-46,390,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Mustang Bio employs 38 workers across the globe.

What is Mustang Bio's official website?

The official website for Mustang Bio is www.mustangbio.com.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.